Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Breast Cancer Patients Sensitive to Hormonal Therapy
Status:
Completed
Trial end date:
2018-01-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the activity of molecular response in endocrine
sensitive breast cancer HER2+/HR+ patients treated with Pertuzumab-trastuzumab plus
Ietrozole.
Phase:
Phase 2
Details
Lead Sponsor:
Istituto Oncologico Veneto IRCCS
Collaborators:
Association for Translational Research in Oncology (AS.T.R.O.) Translational Research in Oncology